The local medical sector is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in scientific trials for addressing obesity. This https://socialmediaentry.com/story7282805/retatrutide-australia-australia-a-emerging-solution-for-weight-loss